The role of PRAME immunohistochemistry in the diagnostic approach to melanocytic lesions

As a regional leader in advanced and integrated solutions in pathology and diagnostic testing, Roche Diagnostics Australia joined the XXXIV International Congress of the International Academy of Pathology as a platinum sponsor.
Contributing to the scientific program of the event held in Sydney in October 2022, Roche sponsored a symposium by Dr Robert Rawson, an Australian pathologist associated with the Melanoma Institute Australia and Royal Prince Alfred Hospital.
This is a recording of his presentation on PRAME, a tumour-associated antigen identified by an autologous T-cell epitope in a patient with metastatic cutaneous melanoma.
In his presentation, Dr. Robert Rawson discusses the history and context of PRAME immunohistochemistry, the role in the assessment of cutaneous melanocytic lesions, and other roles of PRAME, including nodal deposits, margin assessment, assessment of melanocytic lesions at other sites, and using PRAME in undifferentiated malignancies.
Subscribe to our KZbin channel now: kzbin.info?su...
Get in touch with us:
www.roche.com/
/ roche
/ roche
/ roche
/ roche
Roche has been committed to improving lives since the company was founded in 1896 in Basel, Switzerland. Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally.
Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.
For more information and insights visit: www.roche.com/

[@Bart9349]

Thank you for that informative and thorough lecture. It will help with our interpretation of the results from PRAME testing, which has gained in popularity.